Product Description
Lansoprazole is safe and effective for the treatment of acid-related disorders. It is more effective than the H2-receptor antagonists and comparable to omeprazole for these indications. Lansoprazole inhibits gastric acid secretion via inhibition of gastric hydrogen/potassium adenosine triphosphatase (H+,K(+)-ATPase), an enzyme of the gastric parietal cell membrane that forms part of the proton pump that performs the final step in the acid secretory process. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/8968456/)
Mechanisms of Action: Proton Pump Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Bile Reflux | Duodenal Ulcer | Esophagitis | Gastroesophageal Reflux
Known Adverse Events: Abdominal Pain | Pain Unspecified | Constipation | Diarrhea
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, China, Czech Republic, Georgia, Hungary, Poland, Serbia, Ukraine, United States, Unknown Location
Active Clinical Trial Count: 5
Highest Development Phases
Phase 2: Duodenal Ulcer|Esophagitis|Peptic Ulcer
Phase 1: Zollinger-Ellison Syndrome
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CX842A2201 | P2 |
Completed |
Esophagitis |
2022-09-01 |
|
| 2020-003319-91 | P2 |
Completed |
Esophagitis |
2022-08-31 |
|
| CTR20181006 | P2 |
Not yet recruiting |
Duodenal Ulcer |
None |
|
| CTR20243909 | P1 |
Recruiting |
Duodenal Ulcer|Esophagitis|Zollinger-Ellison Syndrome |
None |